TabletsClinical Overview
Telmisartan and Chlorthalidone is a potent, long-acting dual antihypertensive combination. Telmisartan delivers selective 24-hour AT1 receptor blockade, while chlorthalidone, a long-acting monosulfonamyl thiazide-like diuretic with a terminal elimination half-life of 40-60 hours, provides sustained intravascular volume and vascular resistance reduction throughout day and night. Indicated for stage 2 hypertension and nocturnal/early morning hypertension surges.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning with water, with or without meals. Maintain consistent daily hydration. Monitor home blood pressure regularly.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, fatigue, electrolyte imbalances (hypokalemia, hyponatremia), hyperuricemia (gout flares), orthostatic lightheadedness. Rare/Severe: Boxed warning: Fetal toxicity; acute renal failure, severe hypokalemia, and cardiac arrhythmias.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Fetal toxicity. Contraindicated in pregnancy, anuria, and severe hepatic failure. Baseline and periodic monitoring of serum potassium, sodium, and creatinine is essential. Caution in patients with history of gout.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Telmisartan 40mg + Hydrochlorothiazide 12.5mg Tablets
Telmisartan and Hydrochlorothiazide combines an AT1 angiotensin II receptor antagonist with a thiazide diuretic. Telmisartan suppresses the renin-angiotensin-aldosterone axis, while hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted renal tubules, increasing urinary excretion of sodium, chloride, and water. Telmisartan counteracts diuretic-induced potassium wasting and metabolic disturbances. Indicated for the treatment of hypertension not adequately controlled on telmisartan monotherapy.
Telmisartan Tablets 20mg
Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.
Telmisartan Tablets 40mg
Telmisartan is a potent, non-peptide, long-acting angiotensin II type 1 (AT1) receptor antagonist on the WHO Model List of Essential Medicines. It exhibits an exceptionally long elimination half-life (around 24 hours) providing sustained 24-hour blood pressure control with high trough-to-peak ratio, and uniquely functions as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma), improving glucose handling and lipid metabolism. Indicated for essential hypertension and cardiovascular risk reduction in patients with coronary artery disease, stroke, or diabetes with end-organ damage.
Telmisartan 40mg + Amlodipine 5mg Tablets
Telmisartan and Amlodipine is a synergistic dual antihypertensive formulation. Telmisartan blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II at AT1 receptors and improves insulin sensitivity via partial PPAR-gamma agonism, while amlodipine selectively inhibits transmembrane calcium influx in vascular smooth muscle, producing peripheral arteriolar vasodilation. Telmisartan post-capillary venodilation mitigates amlodipine-induced pre-capillary peripheral ankle edema. Indicated for essential hypertension in patients whose blood pressure is not adequately controlled on monotherapy.